P08684 (CP3A4_HUMAN) Homo sapiens (Human)
Cytochrome P450 3A4 UniProtKBInterProSTRINGInteractive Modelling
503 aa; Sequence (Fasta) ;
1 identical sequence: Homo sapiens: Q6GRK0
It is possible new templates exist for this target since these models were created.
Available Structures
101 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Human CYP3A4 bound to a suicide substrate | homo-4-mer | 97.03 | 4×HEM; 4×MWS; | |||
| Human CYP3A4 bound to a drug mibefradil | homo-4-mer | 97.67 | 4×HEM; 4×MWV; 8×EDO; 4×DMS; | |||
| Crystal structure of human CYP3A4 bound to an inhibitor | homo-4-mer | 97.88 | 4×HEM; 4×DJ1; | |||
| Crystal structure of human CYP3A4 bound to an inhibitor | homo-4-mer | 98.08 | 4×HEM; 4×D7Y; | |||
| Crystal structure of human CYP3A4 bound to an inhibitor | homo-4-mer | 97.44 | 4×HEM; 4×80K; | |||
| Human CYP3A4 bound to a drug substrate | homo-4-mer | 96.38 | 4×HEM; 4×GOL; 4×MWY; | |||
| Crystal structure of human CYP3A4 bound to an inhibitor | homo-4-mer | 97.65 | 4×HEM; 4×D7M; | |||
| Crystal structure of the midazolam-bound human CYP3A4 | homo-3-mer | 98.53 | 3×HEM; 3×08J; | |||
| Human CYP3A4 bound to PMSF | homo-2-mer | 98.09 | 2×HEM; 4×GOL; 2×PMF; 14×EDO; 2×DMS; | |||
| Human CYP3A4 bound to an inhibitor fluconazole | homo-2-mer | 97.88 | 2×HEM; 2×TPF; 2×DMS; 2×EDO; | |||
| Human CYP3A4 bound to a substrate | homo-2-mer | 99.15 | 2×HEM; 12×CFF; | |||
| Human CYP3A4 bound to an inhibitor metyrapone | homo-2-mer | 98.73 | 2×HEM; 2×GOL; 2×MYT; 2×EDO; | |||
| Human CYP3A4 bound to a substrate | homo-2-mer | 98.31 | 2×HEM; 2×UC7; 2×GOL; | |||
| Crystal structure of the cysteine depleted CYP3A4 bound to glycerol | homo-2-mer | 96.39 | 2×HEM; 24×GOL; | |||
| Human CYP3A4 bound to three caffeine molecules | homo-2-mer | 99.15 | 2×HEM; 6×CFF; | |||
| Crystal structure of CYP3A4 bound to an inhibitor | homo-2-mer | 94.9 | 2×HEM; 2×X2Q; | |||
| Crystal structure of the cysteine depleted CYP3A4 bound to ritonavir | homo-2-mer | 95.75 | 2×HEM; 2×RIT; | |||
| CYP3A4 bound to an inhibitor | homo-2-mer | 98.09 | 2×HEM; 2×NJ0; | |||
| Crystal structure of CYP3A4 bound to an inhibitor | homo-2-mer | 97.24 | 2×HEM; 2×X2B; | |||
| Crystal structure of CYP3A4 bound to an inhibitor | homo-2-mer | 92.14 | 2×HEM; 2×X1I; | |||
| Crystal structure of CYP3A4 bound to an inhibitor | homo-2-mer | 96.39 | 2×HEM; 2×X0E; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 97.24 | 2×HEM; 3×GOL; 2×NXR; | |||
| Crystal structure of human CYP3A4 bound to an inhibitor | homo-2-mer | 98.09 | 2×HEM; 2×DEJ; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 96.18 | 2×HEM; 2×QEA; | |||
| Crystal structure of the cysteine depleted CYP3A4 bound to bromoergocryptine | homo-2-mer | 96.81 | 2×HEM; 2×08Y; 8×GOL; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 98.08 | 2×HEM; 2×NJO; | |||
| Crystal structure of CYP3A4 bound to an inhibitor | homo-2-mer | 95.53 | 2×HEM; 2×X1C; | |||
| Crystal structure of CYP3A4 bound to an inhibitor | homo-2-mer | 96.17 | 2×HEM; 2×X2Q; | |||
| Crystal structure of human CYP3A4 bound to an inhibitor | homo-2-mer | 98.3 | 2×HEM; 2×D7J; | |||
| CYP3A4 bound to an inhibitor | homo-2-mer | 94.04 | 2×HEM; 2×NH0; | |||
| CYP3A4 bound to an inhibitor | homo-2-mer | 95.32 | 2×HEM; 2×NI6; | |||
| Crystal structure of human CYP3A4 with the caged inhibitor | homo-2-mer | 96.38 | 2×HEM; 2×GOL; 2×X8S; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 97.23 | 2×HEM; 2×X7J; 2×SO4; 2×GOL; 1×EDO; | |||
| CYP3A4 bound to an inhibitor | homo-2-mer | 92.77 | 2×HEM; 2×QDJ; | |||
| Crystal structure of human CYP3A4 bound to metformin | homo-2-mer | 96.38 | 2×MF8; 2×HEM; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 92.55 | 2×HEM; 2×QDV; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 95.53 | 2×HEM; 2×QE4; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 98.08 | 2×HEM; 2×T0K; | |||
| Crystal structure of CYP3A4 bound to an inhibitor | homo-2-mer | 94.24 | 2×HEM; 2×X1O; | |||
| Crystal structure of human CYP3A4 bound to an inhibitor | homo-2-mer | 93.6 | 2×HEM; 2×DEV; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 96.59 | 2×HEM; 2×QEP; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 97.02 | 2×HEM; 1×SO4; 2×GOL; 2×EDO; 2×X74; | |||
| Crystal structure of human CYP3A4 with the caged inhibitor | homo-2-mer | 94.24 | 2×HEM; 2×X8P; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 95.95 | 2×HEM; 2×GOL; 2×X7P; | |||
| Crystal structure of human CYP3A4 bound to an inhibitor | homo-2-mer | 97.23 | 2×HEM; 2×Y83; | |||
| Crystal structure of human CYP3A4 with the caged inhibitor | homo-2-mer | 94.46 | 2×HEM; 2×O3L; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 88.49 | 2×HEM; 2×X7M; | |||
| Crystal structure of human CYP3A4 bound to ritonavir | homo-2-mer | 98.72 | 2×HEM; 2×RIT; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 96.59 | 2×HEM; 2×X6J; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 96.8 | 2×HEM; 2×X71; | |||
| Crystal structure of human CYP3A4 bound to the testosterone dimer | homo-2-mer | 96.59 | 2×HEM; 2×YNV; | |||
| Crystal structure of human CYP3A4 bound to glycerol | homo-2-mer | 97.65 | 2×HEM; 16×GOL; 24×EDO; | |||
| Crystal structure of CYP3A4 bound to an inhibitor | homo-2-mer | 94.66 | 2×HEM; 2×X4E; | |||
| Crystal structure of CYP3A4 bound to an inhibitor | homo-2-mer | 95.3 | 2×HEM; 2×WZN; | |||
| Crystal structure of CYP3A4 bound to an inhibitor | homo-2-mer | 92.09 | 2×HEM; 2×WZN; | |||
| Crystal structure of human CYP3A4 bound to an inhibitor | homo-2-mer | 97.65 | 2×HEM; 2×D81; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 93.8 | 2×HEM; 2×A1APA; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 96.58 | 2×HEM; 2×QES; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 94.66 | 2×HEM; 2×QDY; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 97.65 | 2×HEM; 1×SO4; 2×X6S; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 96.58 | 2×HEM; 2×X6V; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 96.8 | 2×HEM; 1×PO4; 2×NYF; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 97.01 | 2×HEM; 1×SO4; 1×GOL; 3×EDO; 2×X7D; | |||
| Crystal structure of human CYP3A4 with the caged inhibitor | homo-2-mer | 93.16 | 2×HEM; 2×O39; | |||
| Human CYP3A4 bound to an inhibitor | homo-2-mer | 97.01 | 2×HEM; 2×X5Y; | |||
| CYP3A4 bound to an inhibitor | homo-2-mer | 91.22 | 2×HEM; | |||
| Crystal structure of human cytochrome P450 3A4 | monomer | 95.37 | 1×HEM; | |||
| Crystal structure of human cytochrome P450 3A4 | monomer | 96.83 | 1×STR; 1×HEM; | |||
| Crystal structure of human cytochrome P450 3A4 | monomer | 95.99 | 1×MYT; 1×HEM; | |||
| Crystal Structure of Human Microsomal P450 3A4 | monomer | 99.15 | 1×HEM; | |||
| Crystal structure of cytochrome P450 3A4 bound to progesterone | monomer | 97.88 | 1×STR; 1×HEM; | |||
| Crystal structure of cytochrome P450 3A4 bound to progesterone and citrate | monomer | 98.52 | 1×HEM; 1×STR; 1×CIT; | |||
| Cytochrome P450 3A4 bound to an inhibitor | monomer | 97.67 | 1×HEM; 1×J9K; 2×GOL; | |||
| Crystal structure of CYP3A4 in complex with an inhibitor | monomer | 97.67 | 1×HEM; 1×2QH; | |||
| Human CYP3A4 bound to an inhibitor | monomer | 95.96 | 1×HEM; 1×G0M; | |||
| Human CYP3A4 bound to an inhibitor | monomer | 95.96 | 1×HEM; 1×G1J; | |||
| Human CYP3A4 bound to an inhibitor | monomer | 95.75 | 1×HEM; 1×G0D; | |||
| Human CYP3A4 bound to an inhibitor | monomer | 97.02 | 1×HEM; 1×FZV; | |||
| Crystal structure of human CYP3A4 coordinated to a water molecule | monomer | 98.94 | 1×HEM; | |||
| Human CYP3A4 bound to an inhibitor | monomer | 96.6 | 1×HEM; 1×GOL; 1×G1D; | |||
| Crystal structure of CYP3A4 ligated to oxazole-substituted desoxyritonavir | monomer | 97.66 | 1×HEM; 1×Z8Z; | |||
| Human CYP3A4 bound to an inhibitor | monomer | 95.96 | 1×HEM; 1×G0Y; | |||
| Human CYP3A4 bound to an inhibitor | monomer | 95.96 | 1×HEM; 1×G0J; | |||
| Complex of human CYP3A4 with a desoxyritonavir analog | monomer | 95.75 | 1×HEM; 2×5AW; | |||
| Cytochrome P450 3A4 bound to imidazole and an inhibitor | monomer | 98.08 | 1×HEM; 1×PK9; 1×IMD; 4×GOL; | |||
| Crystal structure of the cytochrome P4503A4-bromoergocryptine complex | monomer | 97.23 | 1×HEM; 1×08Y; | |||
| Cytochrome P450 3A4 bound to an inhibitor | monomer | 98.08 | 1×PK9; 1×HEM; | |||
| Human CYP3A4 bound to an inhibitor | monomer | 95.95 | 1×HEM; 1×FZV; 1×GOL; 1×GLN; | |||
| Complex of CYP3A4 with a desoxyritonavir analog | monomer | 97.02 | 1×HEM; 2×1RD; | |||
| Complex of CYP3A4 with a desoxyritonavir analog | monomer | 97.23 | 1×HEM; 1×6AW; | |||
| Human CYP3A4 bound to an inhibitor | monomer | 96.8 | 1×HEM; 1×GOL; 1×G0D; | |||
| Cytochrome P450 3A4 bound to an inhibitor | monomer | 97.87 | 1×HEM; 1×PKT; | |||
| Crystal structure of human P450 3A4 in complex with ketoconazole | monomer | 97.02 | 1×HEM; 2×KLN; | |||
| Cytochrome P450 (CYP) 3A4 crystallized with clotrimazole | monomer | 96.8 | 1×HEM; 1×CL6; | |||
| Crystal structure of human cytochrome P4503A4 bound to an inhibitor ritonavir | monomer | 97.65 | 4×DMS; 1×HEM; 1×RIT; | |||
| Crystal Structure of the complex between human cytochrome P450 3A4 and desthiazolylmethyloxycarbony… | monomer | 95.94 | 1×HEM; 1×D0R; | |||
| Human CYP3A4 bound to an inhibitor | monomer | 93.16 | 1×HEM; 1×GOL; 1×G0V; | |||
| Complex of human CYP3A4 with a desoxyritonavir analog | monomer | 97.86 | 1×HEM; 1×7AW; | |||
| Crystal structure of human P450 3A4 in complex with erythromycin | monomer | 95.3 | 1×HEM; 1×ERY; | |||
| Complex of human CYP3A4 with a desoxyritonavir analog | monomer | 95.94 | 1×HEM; 1×8AW; | |||
| Crystal structure of CYP3A4 ligated to pyridine-substituted desoxyritonavir | monomer | 97.65 | 1×HEM; 1×Z9Z; | |||
2 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8so1.1.B | monomer | 0.87 | 1×HEM; 3×CFF; | 100.00 | ||
| 8so1.1.B | homo-2-mer | 0.87 | 2×HEM; 6×CFF; | 100.00 | ||